Lynda Chin, MD
Associate Vice Chancellor for Health Transformation & CIO for Health Affairs, University of Texas System; CEO Apricity Health
FEE RANGE: $3,000–$12,000 [FEE NOTE]
TRAVELS FROM: Texas
An elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in the application of analytical technologies, AI/ML, and big data in medicine. Her groundbreaking work synthesizing terabyte-scale datasets in genomics and oncology research has opened new frontiers in digital medicine. Dr. Chin is the President and CEO of Apricity Health, a next-generation precision oncology company she co-founded, with a mission to leverage digital technologies to bring novel therapies and better care to more patients, and harness real-world patient data to drive better cancer drug discovery. Dr. Chin is the PResident adn CEO of Apricity Health.
An elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in the application of analytical technologies, AI/ML, and big data in medicine. Her groundbreaking work synthesizing terabyte-scale datasets in genomics and oncology research has opened new frontiers in digital medicine.
As founding chair of the Department of Genomic Medicine at the University of Texas MD Anderson Cancer Center, Dr. Chin launched projects to transform workflows for patient-oriented research harness high-velocity clinical and research data, and democratize cancer care expertise across a network of global partner care centers. As Chief Innovation Officer of the University of Texas System, she forged initiatives to create infrastructure for more equitable access to care for underserved populations. In her work at The Cancer Genome Atlas (TCGA), she was Principal Investigator driving development of the Firehose data pipeline, served on the Scientific Steering Committee of the International Cancer Genome Consortium (ICGC), and is actively involved in conceptualizing the next phase of ICGC, ICGC-ARGO (Accelerating Research on Genomic Oncology).
Dr. Chin earned a B.A. degree from Brown University and a M.D. degree from Albert Einstein College of Medicine. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and Montefiore Medical Center in NY and went on to a productive academic research career at Dana-Farber Cancer Institute, where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard.
Prior to joining the UT System in 2015, Dr. Chin was the founding chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at UT MD Anderson Cancer Center. She has made multiple scientific discoveries spanning the fields of transcription, telomere biology, cancer genomics, and personalized cancer medicine, and more recently big data and cognitive analytics. Dr. Chin is internationally known for her pioneering work in genomics and analytics and has won numerous distinguished honors for her scientific contributions.
Presently, Dr. Chin is the President and CEO of Apricity Health, a next-generation precision oncology company she co-founded, with a mission to leverage digital technologies to bring novel therapies and better care to more patients, and harness real-world patient data to drive better cancer drug discovery.
“Dr. Chin is a thought leader in developing bold and innovative health care solutions,” said Ray Greenberg, M.D., Ph.D., executive vice chancellor for health affairs. “The National Academies’ committee – and the nation’s health care policy – will benefit greatly from Dr. Chin’s expertise and vision."
As founding chair of the Department of Genomic Medicine at the University of Texas MD Anderson Cancer Center, Dr. Chin launched projects to transform workflows for patient-oriented research harness high-velocity clinical and research data, and democratize cancer care expertise across a network of global partner care centers. As Chief Innovation Officer of the University of Texas System, she forged initiatives to create infrastructure for more equitable access to care for underserved populations. In her work at The Cancer Genome Atlas (TCGA), she was Principal Investigator driving development of the Firehose data pipeline, served on the Scientific Steering Committee of the International Cancer Genome Consortium (ICGC), and is actively involved in conceptualizing the next phase of ICGC, ICGC-ARGO (Accelerating Research on Genomic Oncology).
Dr. Chin earned a B.A. degree from Brown University and a M.D. degree from Albert Einstein College of Medicine. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and Montefiore Medical Center in NY and went on to a productive academic research career at Dana-Farber Cancer Institute, where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard.
Prior to joining the UT System in 2015, Dr. Chin was the founding chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at UT MD Anderson Cancer Center. She has made multiple scientific discoveries spanning the fields of transcription, telomere biology, cancer genomics, and personalized cancer medicine, and more recently big data and cognitive analytics. Dr. Chin is internationally known for her pioneering work in genomics and analytics and has won numerous distinguished honors for her scientific contributions.
Presently, Dr. Chin is the President and CEO of Apricity Health, a next-generation precision oncology company she co-founded, with a mission to leverage digital technologies to bring novel therapies and better care to more patients, and harness real-world patient data to drive better cancer drug discovery.
“Dr. Chin is a thought leader in developing bold and innovative health care solutions,” said Ray Greenberg, M.D., Ph.D., executive vice chancellor for health affairs. “The National Academies’ committee – and the nation’s health care policy – will benefit greatly from Dr. Chin’s expertise and vision."
Topics:
- Corss-Sector Collaborations to Engage, Empower, and Enhance Care for the Underserved Populations
- COVID-19: How the Pandemic Reinforces the Value of Patient-centric Approach
Dr. Chin discusses how the pandemic is reinforcing the value of patient-centric approach… and by shifting the point-of-care and bringing clinical trials to patients’ homes, we are also narrowing the access disparity, especially for specialty care (like cancer) and novel therapies (like clinical trials). - Can Medical Industry and Medical Research Live Happily Ever After?
- Big Data and AI: Transforming Research and Care
- Building a Patient-Centric, Interoperable, Digitally Connected Healthcare Ecosystem
Looking for a speaker not on our website? Just ask! Not all speakers are listed.
Let us help you. All fields are required.